首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Inhibitors of acetyltransferase domain of N-acetylglucosamine-1-phosphate-uridyltransferase/glucosamine-1-phosphate-acetyltransferase (GlmU). Part 1: Hit to lead evaluation of a novel arylsulfonamide series
Authors:Green Oluyinka M  McKenzie Andrew R  Shapiro Adam B  Otterbein Ludovic  Ni Haihong  Patten Arthur  Stokes Suzanne  Albert Robert  Kawatkar Sameer  Breed Jason
Institution:Infection Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, MA 02451, USA. oluyinka.green@astrazeneca.com
Abstract:A novel arylsulfonamide-containing series of compounds represented by 1, discovered by highthroughput screening, inhibit the acetyltransferase domain of N-acetylglucosamine-1-phosphate-uridyltransferase/glucosamine-1-phosphate-acetyltransferase (GlmU). X-ray structure determination confirmed that inhibitor binds at the site occupied by acetyl-CoA, indicating that series is competitive with this substrate. This letter documents our early hit-to-lead evaluation of the chemical series and some of the findings that led to improvement in in-vitro potency against Gram-negative and Gram-positive bacterial isozymes, exemplified by compound 40.
Keywords:
本文献已被 ScienceDirect PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号